AvroBio Inc TECX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$20.64 up $1.22, 6.28% at close Nov 6
Last close · Previous close $19.42
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$4.63Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$20.64up $1.22, 6.28%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$19.42Nov 5
- Volume310.82KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume177.79KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $16.77 to $39.53; now $20.64
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
TECX trailed the S&P 500 in all 6 periods.
| Period | TECX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TECX: down 7.9% S&P 500: down 5.6% | TECX trailed the S&P 500 by 2.3 percentage points Trailed |
| 3M | TECX: down 31.7% S&P 500: down 4.1% | TECX trailed the S&P 500 by 27.6 percentage points Trailed |
| YTD | TECX: down 1.1% S&P 500: up 8.7% | TECX trailed the S&P 500 by 9.8 percentage points Trailed |
| 1Y | TECX: up 8.7% S&P 500: up 10.9% | TECX trailed the S&P 500 by 2.2 percentage points Trailed |
| Long term | ||
| 3Y | TECX: up 13.9% S&P 500: up 75.0% +4.4% vs +20.5% a year | TECX trailed the S&P 500 by 61.1 percentage points Trailed |
| 5Y | TECX: down 71.3% S&P 500: up 67.8% −22.1% vs +10.9% a year | TECX trailed the S&P 500 by 139.1 percentage points Trailed |
$10,000 invested in TECX 5 years ago (Nov 5, 2021) would be worth about $2,871 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
TECX trailed the S&P 500 in all 6 periods.
| Period | TECX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TECX: down 7.9% S&P 500: down 5.6% | TECX trailed the S&P 500 by 2.3 percentage points Trailed |
| 3M | TECX: down 31.7% S&P 500: down 4.3% | TECX trailed the S&P 500 by 27.4 percentage points Trailed |
| YTD | TECX: down 1.1% S&P 500: up 7.8% | TECX trailed the S&P 500 by 8.9 percentage points Trailed |
| 1Y | TECX: up 8.7% S&P 500: up 9.7% | TECX trailed the S&P 500 by 1.0 percentage points Trailed |
| Long term | ||
| 3Y | TECX: up 13.9% S&P 500: up 68.8% +4.4% vs +19.1% a year | TECX trailed the S&P 500 by 54.9 percentage points Trailed |
| 5Y | TECX: down 71.3% S&P 500: up 56.9% −22.1% vs +9.4% a year | TECX trailed the S&P 500 by 128.2 percentage points Trailed |
$10,000 invested in TECX 5 years ago (Nov 5, 2021) would be worth about $2,871 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$632.40
Closing high on . Now 96.7% below that record.
Split-adjusted daily closes since Jun 21, 2018.
Stock splits
1
1-for-12 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$88.10M
- Diluted EPS
- −$4.63
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$12.37M | $0.33 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$15.91M | −$0.93 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$19.98M | −$1.07 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$19.04M | −$1.02 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$19.23M | −$1.03 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$25.24M | −$1.34 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$22.29M | −$1.18 |
| Q3 FY26 (Sep 30, 2026) | $0.00 | −$21.35M | −$1.08 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$119.13M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$105.89M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$42.82M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$57.98M | −$6.83 |
| FY25 (Dec 31, 2025) | $0.00 | −$74.15M | −$4.05 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$69.31MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$69.23MLast 12 months
- Capital spending$78.00KLast 12 months
Shareholder returns
- $36.03MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $235.15MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$3.92MAs of Sep 30, 2026
- Net cash$231.23MAs of Sep 30, 2026
- 19.71As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.02As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −37.7%Last 12 months
Over the last 12 months, AvroBio lost money: its net loss was 37.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −35.6%Last 12 months
Over the last 12 months, AvroBio’s net loss was 35.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About AvroBio Inc
AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
TECX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
TECX stock FAQ
What is TECX stock’s price today?
AvroBio (TECX) traded at $20.64 at the close on , up $1.22 (6.28%) from the previous close of $19.42. Over the past 52 weeks it has traded between $16.77 and $39.53.
If you invested $1,000 in TECX 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in TECX on would be worth about $287 at the close on , a total return of −71.3%. The same $1,000 would be worth $1,087 if invested one year ago. Past performance doesn’t predict future returns.
What is TECX’s P/E ratio?
TECX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$4.63).
What are TECX’s earnings per share?
TECX’s diluted earnings per share were −$4.63 over the four quarters to , compared with −$2.69 in the twelve months before. The latest quarter (Q3 FY26) brought −$1.08 per share, against −$1.02 a year earlier (how EPS works).
Does TECX pay a dividend?
AvroBio hasn’t paid a dividend in the last twelve months.
What is TECX’s 52-week high and low?
Over the past 52 weeks TECX has traded as low as $16.77 and as high as $39.53. At $20.64 at the close on , it is 47.8% below that high and 23.1% above the low.
What is TECX’s all-time high?
TECX’s highest closing price was $632.40 on , adjusted for stock splits. At $20.64 at the close on , it is 96.7% below that record.
Has TECX stock ever split?
Yes, once: 1-for-12 on .
How has TECX stock performed?
Including dividends and measured to the close on , TECX has returned −1.1% so far this year and +8.7% over the past year, and −71.3% over five years (−22.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is AvroBio in?
AvroBio is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does TECX trade on?
AvroBio trades on the Nasdaq under the ticker symbol TECX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.